Skip to main content
Top
Published in: Techniques in Coloproctology 8/2020

01-08-2020 | Crohn's Disease | How I Do It

Mesenchymal stem cells in perianal Crohn’s disease

Authors: H. Guadalajara, M. García-Arranz, M. Dolores Herreros, K. Borycka-Kiciak, A. L. Lightner, D. García-Olmo

Published in: Techniques in Coloproctology | Issue 8/2020

Login to get access

Abstract

The use of mesenchymal stem cells has resulted in a breakthrough for the treatment of complex perianal fistulas in Crohn’s disease. This novel treatment is associated with a minimally invasive surgical technique that can be well defined. However, our previous experience has taught us that neglecting any of the critical steps in the operation can result in frequent treatment failure. We have put together a comprehensive guide, a stepwise algorithm, for our minimally invasive approach to identify common pitfalls and reduce treatment failures. Using data we have collected over the past 15 years from drug development, execution of clinical trials, and enacting an advanced educational training program, we spelt out each stage of the minimally invasive surgical intervention for stem cell delivery for perianal Crohn’s disease. In this article, we provide 21 tips for a correct approach during the five major phases of the surgical procedure. To optimize the efficacy of mesenchymal stem cells for perianal Crohn’s disease, a standardized minimally invasive technique including a reliable and reproducible series of key steps should be utilized.
Literature
1.
go back to reference Dejaco C, Harrer M, Waldhoer T et al (2003) Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 18:1113–1120CrossRef Dejaco C, Harrer M, Waldhoer T et al (2003) Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 18:1113–1120CrossRef
2.
go back to reference Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540PubMed Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540PubMed
3.
go back to reference Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387CrossRef Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387CrossRef
4.
go back to reference Turunen U, Färkkilä M, Valtonen V, Seppälä K (1993) Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology 104:A793 (Abst) Turunen U, Färkkilä M, Valtonen V, Seppälä K (1993) Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology 104:A793 (Abst)
5.
go back to reference Solomon MJ, McLeod RS, O’Connor BI, Steinhart AH, Greenberg GR, Cohen Z (1993) Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol 7:571–573CrossRef Solomon MJ, McLeod RS, O’Connor BI, Steinhart AH, Greenberg GR, Cohen Z (1993) Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol 7:571–573CrossRef
6.
go back to reference Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 122:132–142CrossRef Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 122:132–142CrossRef
7.
go back to reference Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64CrossRef Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64CrossRef
8.
go back to reference O’Brien JJ, Bayless TM, Bayless JA (1991) Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology 101:39–46CrossRef O’Brien JJ, Bayless TM, Bayless JA (1991) Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology 101:39–46CrossRef
9.
go back to reference Sandborn WJ, van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ (1995) An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology 109:1808–1817CrossRef Sandborn WJ, van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ (1995) An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology 109:1808–1817CrossRef
10.
go back to reference Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR et al (1999) Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 117:527–535CrossRef Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR et al (1999) Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 117:527–535CrossRef
11.
go back to reference Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876–885CrossRef Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876–885CrossRef
12.
go back to reference van Koperen PJ, Safiruddin F, Bemelman WA, Slors JF (2009) Outcome of surgical treatment for fistula in ano in Crohn's disease. Br J Surg 96:675–679CrossRef van Koperen PJ, Safiruddin F, Bemelman WA, Slors JF (2009) Outcome of surgical treatment for fistula in ano in Crohn's disease. Br J Surg 96:675–679CrossRef
13.
go back to reference Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR (2004) Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg 91:476–480CrossRef Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR (2004) Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg 91:476–480CrossRef
14.
go back to reference Jeon M, Song K, Koo J, Kim S (2019) Evaluation of a seton procedure combined with infliximab therapy (early vs. late) in perianal fistula with Crohn disease. Ann Coloproctol 3:249–253CrossRef Jeon M, Song K, Koo J, Kim S (2019) Evaluation of a seton procedure combined with infliximab therapy (early vs. late) in perianal fistula with Crohn disease. Ann Coloproctol 3:249–253CrossRef
15.
go back to reference Sebastian S, Black C, Pugliese D et al (2018) The role of multimodal treatment in Crohn’s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther 48:941–950CrossRef Sebastian S, Black C, Pugliese D et al (2018) The role of multimodal treatment in Crohn’s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther 48:941–950CrossRef
16.
go back to reference Thompson DL, Lum KD, Nygaard SC, Kuestner RE, Kelly KA, Gimble JM et al (1998) The derivation and characterization of stromal cell lines from the bone marrow of p53−/− mice: new insights into osteoblast and adipocyte differentiation. J Bone Miner Res 13:195–204CrossRef Thompson DL, Lum KD, Nygaard SC, Kuestner RE, Kelly KA, Gimble JM et al (1998) The derivation and characterization of stromal cell lines from the bone marrow of p53−/− mice: new insights into osteoblast and adipocyte differentiation. J Bone Miner Res 13:195–204CrossRef
17.
go back to reference Verfaillie CM, Gupta P, Prosper F, Hurley R, Lundell B, Bhatia R (1999) The hematopoietic microenvironment: stromal extracellular matrix components as growth regulators for human hematopoietic progenitors. Hematology 4:321–333CrossRef Verfaillie CM, Gupta P, Prosper F, Hurley R, Lundell B, Bhatia R (1999) The hematopoietic microenvironment: stromal extracellular matrix components as growth regulators for human hematopoietic progenitors. Hematology 4:321–333CrossRef
18.
go back to reference Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211–228CrossRef Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211–228CrossRef
19.
go back to reference García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA et al (2003) Autologous stem cell transplantation for treatment of rectovaginal fistula in perinatal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis 18:451–454CrossRef García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA et al (2003) Autologous stem cell transplantation for treatment of rectovaginal fistula in perinatal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis 18:451–454CrossRef
20.
go back to reference Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290CrossRef Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290CrossRef
21.
go back to reference Cheng F, Huang Z, Li Z (2019) Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis. Tech Coloproctol 23:613–623CrossRef Cheng F, Huang Z, Li Z (2019) Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis. Tech Coloproctol 23:613–623CrossRef
22.
go back to reference Ciccocioppo R, Klersy C, Leffler DA, Rogers R, Bennett D, Corazza GR (2019) Systematic review with meta-analysis: safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open 3:249–260CrossRef Ciccocioppo R, Klersy C, Leffler DA, Rogers R, Bennett D, Corazza GR (2019) Systematic review with meta-analysis: safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open 3:249–260CrossRef
23.
go back to reference Choi S, Jeon BG, Chae G, Lee SJ (2019) The clinical efficacy of stem cell therapy for complex perianal fistulas: a meta-analysis. Tech Coloproctol 23:411–427CrossRef Choi S, Jeon BG, Chae G, Lee SJ (2019) The clinical efficacy of stem cell therapy for complex perianal fistulas: a meta-analysis. Tech Coloproctol 23:411–427CrossRef
24.
go back to reference Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ et al (2018) Efficacy of medical therapies for fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 16:1879–1892CrossRef Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ et al (2018) Efficacy of medical therapies for fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 16:1879–1892CrossRef
25.
go back to reference Lightner AL, Wang Z, Zubair AC, Dozois EJ (2018) A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn's disease: progress made and future directions. Dis Colon Rectum 61:629–640CrossRef Lightner AL, Wang Z, Zubair AC, Dozois EJ (2018) A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn's disease: progress made and future directions. Dis Colon Rectum 61:629–640CrossRef
26.
go back to reference Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11:135–149CrossRef Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11:135–149CrossRef
27.
go back to reference Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G (2018) ECCO-ESCP consensus on surgery for Crohn's disease. J Crohns Colitis 12:1–16CrossRef Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G (2018) ECCO-ESCP consensus on surgery for Crohn's disease. J Crohns Colitis 12:1–16CrossRef
28.
go back to reference Boscá MM, Alós R, Maroto N, Gisbert JP, Beltrán B, Chaparro M et al (2019) Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. Gastroenterol Hepatol Boscá MM, Alós R, Maroto N, Gisbert JP, Beltrán B, Chaparro M et al (2019) Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. Gastroenterol Hepatol
29.
go back to reference Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W et al (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321–2328CrossRef Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W et al (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321–2328CrossRef
30.
go back to reference Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW et al (2010) Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28:2229–2238CrossRef Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW et al (2010) Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28:2229–2238CrossRef
31.
go back to reference Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C et al (2011) Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25:648–654CrossRef Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C et al (2011) Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25:648–654CrossRef
32.
go back to reference Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al (2018) Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology 154:1334–1342CrossRef Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al (2018) Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology 154:1334–1342CrossRef
Metadata
Title
Mesenchymal stem cells in perianal Crohn’s disease
Authors
H. Guadalajara
M. García-Arranz
M. Dolores Herreros
K. Borycka-Kiciak
A. L. Lightner
D. García-Olmo
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Techniques in Coloproctology / Issue 8/2020
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-020-02250-5

Other articles of this Issue 8/2020

Techniques in Coloproctology 8/2020 Go to the issue